Longitudinal studies of CML patients consistently reported the emergence of BCR::ABL1 in a pre-existing clonal population carrying a clonal hematopoiesis-related mutant, or the expansion of BCR::ABL1-negative clones during therapy [40, 41, 46, 48]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.